The values of AHCY and CBS promoter methylation on the diagnosis of cerebral infarction in Chinese Han population
- PDF / 1,588,871 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 91 Downloads / 174 Views
RESEARCH ARTICLE
Open Access
The values of AHCY and CBS promoter methylation on the diagnosis of cerebral infarction in Chinese Han population Xiaodong Li1, Shufang Bu1, Ran Ran Pan2, Cong Zhou2, Kun Qu3, Xiuru Ying2, Jie Zhong2, Jianhao Xiao4, Qian Yuan4, Simiao Zhang4, Laura Tipton5, Yunliang Wang4*, Youping Deng5* and Shiwei Duan2*
Abstract Background: The goal of our study is to investigate whether the methylation levels of AHCY and CBS promoters are related to the risk of cerebral infarction by detecting the methylation level of AHCY and CBS genes. Methods: We extracted peripheral venous blood from 152 patients with cerebral infarction and 152 gender- and age-matched healthy controls, and determined methylation levels of AHCY and CBS promoters using quantitative methylation-specific polymerase chain reaction. We used the percentage of methylation reference (PMR) to indicate gene methylation level. Results: We compared the promoter methylation levels of two genes (AHCY and CBS) in peripheral blood DNA between the cerebral infarction case group and the control group. Our study showed no significant difference in AHCY promoter methylation between case and control. Subgroup analysis by gender showed that the methylation level of AHCY in males in the case group was lower than that in the control group, but the difference was not statistically significant in females. In a subgroup analysis by age, there was no significant difference in the AHCY methylation level between the case and control in the young group (≤44 years old). However, the level of AHCY gene methylation in the middle-aged group (45–59 years old) was significantly higher and the aged group (≥60 years old) was significantly lower than that in the control groups. However, CBS promoter methylation levels were significantly lower in the case group than in the control group (median PMR: 70.20% vs 104.10%, P = 3.71E-10). In addition, the CBS methylation levels of males and females in the case group were significantly lower than those in the control group (male: 64.33% vs 105%, P = 2.667E-08; female: 78.05% vs 102.8%, P = 0.003). We also found that the CBS levels in the young (23–44), middle-aged (45–59), and older (60–90) groups were significantly lower than those in the control group (young group: 69.97% vs 114.71%; P = 0.015; middle-aged group: 56.04% vs 91.71%; P = 6.744E-06; older group: 81.6% vs 119.35%; P = 2.644E-04). Our ROC curve analysis of CBS hypomethylation showed (Continued on next page)
* Correspondence: [email protected]; [email protected]; [email protected] 4 Department of Neurology, the Second Affiliated Hospital, Zhengzhou University, Zhengzhou 450014, Henan, China 5 Bioinformatics Core, Department of Complementary and Integrative Medicine and John A. Burns School of Medicine, University of Hawai’i, Honolulu, HI 96822, USA 2 School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, China Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under
Data Loading...
